Vdxkd8b1x4ctfl9nyh7z

Richter signed a licensing agreement with Pharmanest to commercialize its proprietary pain relief product for gynaecological use in certain territories

Press Releases   •   Oct 13, 2017 13:22 CEST

Budapest, Stockholm – 12 October 2017 - Gedeon Richter Plc. (‘Richter’) and Pharmanest AB (‘Pharmanest’) today announced that Richter will commercialise Pharmanest’s SHACT (Short Acting Lidocaine) technology, a novel innovative proprietary pain relief pharmaceutical formulation, in Europe, in Latin America and in certain other markets.

Media no image

Leading U.S. gynecologists see significant medical need for Pharmanest’s drug candidate SHACT

Press Releases   •   Mar 17, 2016 21:48 CET

SOLNA, SWEDEN, MARCH 17, 2016. Every year millions of women are exposed to pain during gynecological procedures, including IUD (intrauterine device) placements. This is due to the lack of effective and user-friendly therapy for pain relief. The Swedish pharmaceutical company Pharmanest is developing a new pain relief treatment which recently received very positive reviews from leading physicians and scientists at a meeting of experts, arranged by the company in the United States.

In December 2015, Pharmanest gathered leading U.S. gynecologists in Dallas, Texas, to discuss how its drug candidate SHACT should be used to best meet women's needs for pain relief during gynecological procedures. The meeting emphasized that the need for pain relief is enormous - patients' first question to the treating physician is usually: "Will it hurt?". After a careful review of the available documentation, the experts concluded that SHACT has good prospects to easily and safely reduce patients' pain perception.

“More and more U.S. women are selecting intrauterine devices as their method of birth control because of their high level of efficacy and convenience. IUDs are usually placed during a short procedure in a doctor’s office, but women may worry about any pain and discomfort they might feel during the procedure. The delegates at the expert meeting are all excited that a product like SHACT could help women more comfortably get these effective contraceptives. SHACT also has a potential to reduce pain within a wide range of gynecologic procedures”, says Anita L. Nelson, M.D., Professor of Obstetrics and Gynecology, Los Angeles, one of the specialist physicians attending the meeting.

The positive assessment of the expert group is based on extensive preclinical and clinical documentation, including a controlled clinical trial showing that SHACT provides fast pain relief during intrauterine device placements.

Gunvor Ekman-Ordeberg, Professor of Obstetrics and Gynecology at the Karolinska Institute and Board Director of Pharmanest summarizes the meeting: "A clinical study of 200 patients shows that SHACT in a significant way reduces pain and discomfort associated with IUD placement. These positive results have attracted great interest from leading gynecologists around the world, most recently at the meeting with the U.S. expert group in Dallas."

Preparation of the commercialization of SHACT in Europe is already in a final stage, while decisions and planning of a Phase III trial for registration in the U.S. will take place in the near future. SHACT is patent protected until at least 2031 in most parts of the world. To the company's knowledge, there are currently no similar commercially available products for topical pain relief with documented efficacy.

"Women’s need of pain relief was distinctly confirmed by this group of leading U.S. gynecologists. Pharmanest will now do its utmost to make SHACT available for all those women who are exposed to pain during gynecological procedures. The support of our distinguished advisory board will be of great importance in this important task", says Gunilla Lundmark, CEO, Pharmanest.

About Pharmanest AB

Pharmanest AB is Swedish a privately-held company focused on new products for pain relief in the gynecology and obstetrics field.Pharmanest is specialized in the development of new topical analgesic formulations to be used on the mucosa. Pharmanest’s lead product, SHACT, is a unique proprietary short-acting formulation of lidocaine for pain relief with the lead indication treatment of pain during intrauterine device (“IUD”) placement. The clinical data generated so far clearly demonstrates that SHACT may play an important role in pain management within the gynecological procedure segment.

For more information on Pharmanest, please visit www.pharmanest.se

Millions of women are exposed to pain during gynecological procedures, including IUD (intrauterine device) placements. This is due to the lack of effective and user-friendly therapy for pain relief. The Swedish pharmaceutical company Pharmanest is developing a new pain relief treatment which recently received very positive reviews from leading gynecologists at a meeting of experts in the U.S.

Read more »
Media no image

Pharmanest genomför nyemission om 30 miljoner SEK och får nya storägare

News   •   Jul 14, 2015 10:27 CEST

Pharmanest genomför nyemission om 30 miljoner SEK och får nya storägare

Stockholm, 14 juli 2015. Pharmanest AB meddelade idag att bolaget framgångsrikt genomfört en nyemission om cirka 30 miljoner SEK till nya och befintliga ägare. Östersjöstiftelsen, Recipharm Venture Fund och Praktikerinvest blir nya betydande aktieägare genom sitt deltagande i emissionen och ett samtidigt förvärv av den tidigare majoritetsägaren Karolinska Developments andel i bolaget. Pharmanest välkomnar också Kåre Gilstring som ny aktieägare. Som en följd av ägarförändringarna har Håkan Wallin valts till ny styrelseordförande och Lars Irestedt och Carl-Johan Spak till nya styrelseledamöter.

Pharmanest utvecklar lokalverkande läkemedel för att minska den smärta många kvinnor upplever i samband med gynekologiska ingrepp. Bolagets längst framskridna projekt – SHACT – har redan genomgått omfattande kliniska prövningar med positiva resultat. Den framgångsrikt genomförda nyemissionen möjliggör för Pharmanest att fortsätta aktiviteterna för att ta SHACT till ett marknadsgodkännande.

”SHACT är en produkt som kan lindra smärtan hos de miljontals kvinnor som genomgår gynekologiska ingrepp utan bedövning.Nu har vi med hjälp av långsiktiga och professionella investerare säkrat de finansiella resurser som behövs för att genomföra de avslutande aktiviteterna inför en kommersialisering”, säger Pharmanests VD, Gunilla Lundmark.

Vid Pharmanests årsstämma den 25 juni 2015 omvaldes styrelseledamöterna Per Langö och Gunvor Ekman-Ordeberg. Nyval skedde av Håkan Wallin (ordförande), Lars Irestedt och Carl-Johan Spak. Alan Raffensperger, Gunilla Ekström och Arne Brodin hade avböjt omval och avtackades för deras insatser i Pharmanest.

Nedan följer en kortfattad beskrivning av de nya styrelseledamöterna.

Håkan Wallin (f. 1962), civ. ek., CEFA, har en mångsidig och lång erfarenhet inom life-science området både på det operativa och strategiska området. Han kommer senast från en position som Executive Vice President Corporate Development på Medivir AB. Tidigare erfarenheter inkluderar bland annat partner och ansvarig för life-science på ABG Sundal Collier AB:s Corporate Finance-avdelning samt styrelseledamot och verkställande direktör i Libertas Capital Nordic AB. Håkan agerar i dag via sitt egna konsultbolag HWA Advisory & Capital AB och är även styrelseledamot i det First North-listade bolaget LightLab Sweden AB.

Lars Irestedt (f. 1941) är en av Pharmanests grundare och verksam som anestesiolog och docent vid Karolinska Universitetssjukhuset i Solna. Han har utfört omfattande forskning inom anestesiområdet och ses allmänt som en av Europas främsta narkosläkare med inriktning på obstetrik. Dr. Irestedt har varit medlem av redaktionsråden för ett antal vetenskapliga tidskrifter, inklusive Acta Anaesthesiologica Scandinavica, International Journal of Obstetric Anesthesia och Scandinavian Journal of Pain.

Carl-Johan Spak (f.1956),Odont. Dr., är Executive Vice President på Recipharm sedan 2011. Han ansvarar där för affärsområdet Development and Technology vilket inbegriper företagets utvecklingsverksamhet och dess egna produkträttigheter. Dessförinnan har Carl-Johan innehaft olika ledande befattningar på Meda och Recip. Carl-Johan är styrelseledamot i flera biotech-bolag, bland annat i Cobra Biologics Holding AB, Kahr Medical Ltd, Prokarium Ltd, och Symcel Sverige AB.

För mer information, vänligen kontakta:

Gunilla Lundmark, VD, Pharmanest AB

Telefon: 070-974 90 57, e-post: gunilla.lundmark@pharmanest.se

14 juli 2015. Pharmanest AB meddelade idag att bolaget framgångsrikt genomfört en nyemission om cirka 30 miljoner SEK till nya och befintliga ägare. Östersjöstiftelsen, Recipharm Venture Fund och Praktikerinvest blir nya betydande aktieägare. Som en följd av ägarförändringarna har Håkan Wallin valts till ny styrelseordförande och Lars Irestedt och Carl-Johan Spak till nya styrelseledamöter.

Read more »
Media no image

Pharmanest completes SEK 30 million rights issue and welcomes new major shareholders

Press Releases   •   Jul 14, 2015 10:17 CEST

Pharmanest completes SEK 30 million rights issue and welcomes new major shareholders

Stockholm, July 14, 2015. Pharmanest AB today announced that the company has successfully completed a rights issue of approximately SEK 30 million to new and existing owners. Östersjöstiftelsen, Recipharm Venture Fund and Praktikerinvest become new major shareholders through their participation in the rights issue and by simultaneously acquiring all shares from the former majority owner, Karolinska Development. Pharmanest also welcomes Kåre Gilstring as new shareholder. As a result of the ownership changes, Håkan Wallin has been elected new Chairman and Lars Irestedt and Carl-Johan Spak new board members.

Pharmanest develops locally acting pharmaceuticals to reduce the pain many women experience during gynecological procedures. The company's most advanced project - SHACT - has already undergone extensive clinical trials with positive results. The successful completion of the rights issue enables Pharmanest to pursue remaining activities with the objective of obtaining market approval for SHACT.

"SHACT is a pharmaceutical product that can ease the pain of the millions of women undergoing gynecological procedures without anesthesia. With the help of long-term and professional investors, we have now secured the financial resources needed to implement the remaining pre-launch activities," said Gunilla Lundmark, CEO at Pharmanest.

On June 25, 2015, Pharmanest’s Annual General Meeting reelected the board members Per Langö and Gunvor Ekman-Ordeberg. Håkan Wallin (chairman), Lars Irestedt and Carl-Johan Spak were elected as new board members. Alan Raffensperger, Gunilla Ekström and Arne Brodin had declined reelection and were thanked for their valuable contributions to Pharmanest.

Brief descriptions of the newly elected board members are provided below.

Håkan Wallin (b. 1962), B.Sc. Business Economics and Management, CEFA, has a diverse and extensive experience in the life science field at both operational and strategic level. His most recent position was as Executive Vice President Corporate Development at Medivir AB. Previous experience includes, among other things, Partner and Head of life science at ABG Sundal Collier AB's Corporate Finance Department and Director and CEO of Libertas Capital Nordic AB. Mr Wallin currently acts through his own consulting firm HWA Advisory & Capital AB and is a board member of the First North-listed company LightLab Sweden AB.

Lars Irestedt (b. 1941), M.D., Ph.D. is a co-founder of Pharmanest and currently serves as an anesthesiologist and associate professor at Karolinska University Hospital. He has carried out extensive research in anesthesia and is widely seen as one of Europe’s foremost obstetric anesthesiologists. Dr. Irestedt has served on Editorial Boards of a number of journals including Acta Anaesthesiologica Scandinavica, International Journal of Obstetric Anesthesia, and Scandinavian Journal of Pain.

Carl-Johan Spak (b.1956), Ph.D. Odontology, is Executive Vice President at Recipharm since 2011. He is responsible for the business area Development and Technology, including the company's development activities and proprietary product rights. Prior to this, Dr. Spak has held various senior positions at Meda and Recip. He serves on the boards of several biotech companies, including Cobra Biologics Holding AB, Kahr Medical Ltd, Prokarium Ltd., and SymCel Sweden AB.

For further information, please contact:

Gunilla Lundmark, CEO, Pharmanest AB

Phone: +46 (0)70-974 90 57, E-mail: gunilla.lundmark@pharmanest.se

About Pharmanest AB

Pharmanest is a Stockholm-based pharmaceutical company, developing new unique formulations based on well-documented active substances. The formulations are applied topically in the cervix and uterus using applicators developed by Pharmanest. The pain relief is obtained immediately, no advanced instrumentation is required and the systemic effect is minimal. Pharmanest’s first product candidate SHACT is developed to be used for pain relief in connection with gynecological procedures. The clinical data generated so far clearly demonstrates that SHACT may play an important role in pain management within the gynecological procedure segment.

For more information on Pharmanest, please visit www.pharmanest.se

July 14, 2015. Pharmanest AB today announced that the company has successfully completed a rights issue of approximately SEK 30 million. Östersjöstiftelsen, Recipharm Venture Fund and Praktikerinvest become new major shareholders through their participation in the rights issue and by simultaneously acquiring all shares from the former majority owner, Karolinska Development.

Read more »

About Pharmanest AB

Pharmanest specializes in developing products for local pain relief in gynecology and obstetrics

About Pharmanest AB
Pharmanest is a Stockholm-based pharmaceutical company, developing new unique formulations based on well-documented active substances. The formulations are applied topically in the cervix and uterus using applicators developed by Pharmanest. The pain relief is obtained immediately, no advanced instrumentation is required and the systemic effect is minimal. Pharmanest’s first product candidate SHACT is developed to be used for pain relief in connection with gynecological procedures. The clinical data generated so far clearly demonstrates that SHACT may play an important role in pain management within the gynecological procedure segment.
For more information on Pharmanest, please visit www.pharmanest.se

Address

  • Pharmanest AB
  • Fogdevreten 2A
  • 171 65 Solna
  • Sweden

Subscribe via RSS